Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is 3.54% higher on its value in year-to-date trading and has touched a low of $14.15 and a high of $26.56 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ACAD stock was last observed hovering at around $19.01 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $19.00, the stock is -0.95% and 4.24% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.29 million and changing -0.05% at the moment leaves the stock 14.41% off its SMA200. ACAD registered -23.33% loss for a year compared to 6-month gain of 19.20%.
The stock witnessed a 4.00% loss in the last 1 month and extending the period to 3 months gives it a 17.43%, and is -3.41% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.77% over the week and 3.56% over the month.
Acadia Pharmaceuticals Inc (ACAD) has around 598 employees, a market worth around $3.16B and $929.24M in sales. Current P/E ratio is 24.60 and Fwd P/E is 20.98. Profit margin for the company is 13.83%. Distance from 52-week low is 34.28% and -28.46% from its 52-week high. The company has generated returns on investments over the last 12 months (20.81%).
The EPS is expected to shrink by -48.11% this year
The shares outstanding are 166.35M, and float is at 165.10M with Short Float at 9.83%.
The top institutional shareholder in the company is BAKER BROS. ADVISORS LP with over 42.88 million shares valued at $$696.77 million. The investor’s holdings represent 25.9001 of the ACAD Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 13.71 million shares valued at $$222.82 million to account for 8.3206 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 13.71 million shares representing 8.2799 and valued at over $$222.75 million, while BLACKROCK INC. holds 7.3194 of the shares totaling 12.06 million with a market value of $$196.01 million.
Acadia Pharmaceuticals Inc (ACAD) Insider Activity
The most recent transaction is an insider sale by Kihara James, the company’s PRINCIPAL ACCOUNTING OFFICER. SEC filings show that Kihara James sold 475 shares of the company’s common stock on Feb 24 ’25 at a price of $19.96 per share for a total of $9481.0. Following the sale, the insider now owns 20228.0 shares.
Acadia Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 24 ’25 that Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER) sold a total of 773 shares of the company’s common stock. The trade occurred on Feb 24 ’25 and was made at $19.96 per share for $15429.0. Following the transaction, the insider now directly holds 53882.0 shares of the ACAD stock.
Still, SEC filings show that on Nov 19 ’24, Teehan Brendan (EVP, COO, HEAD OF COMMERCIAL) disposed off 10,329 shares at an average price of $16.81 for $0.17 million. The insider now directly holds 62,105 shares of Acadia Pharmaceuticals Inc (ACAD).
